Ranibizumab for inflammatory choroidal neovascular membranes

• Research type

  Research Study

• Full title

  A prospective case series of Ranibizumab for the treatment of inflammatory choroidal neovascular membranes secondary to posterior segment intraocular inflammation (PSII)

• IRAS ID

  12219

• Contact name

  Miss Clare Bailey

• Sponsor organisation

  *University Hospitals Bristol NHS Foundation Trust

• Eudract number

  2008-007476-19

• Research summary

  To assess the efficacy and safety of intravitreal Lucentis (Ranibizumab) treatment for inflammatory choroidal neovascularis membranes secondary to posterior segment intraocular inflammation (PSII) or presumed to be secondary to inflammation (idiopathic). Various treatments tried so far include oral/intravenous/intraocular steroids,systemic immuosuppression, Photodynamic therapy or a combination of treatment with variable results. Inravitreal injection of Ranibizumab may help in resolution of CNVM secondary to PSII avoiding the need of systemic therapies. The primary outcome measure is to assess the likelihood of a moderate loss of vision.

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  09/H0106/5

• Date of REC Opinion

  20 Mar 2009

• REC opinion

  Further Information Favourable Opinion